Orphan Therapeutics
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3 Werner Way Ste 210, Lebanon, New Jerse...Website
www.orphantherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Orphan Therapeutics
Orphan Therapeutics LLC is a privately held drug development company founded in 2003, focused on developing terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US. The company licensed its development rights for terlipressin to Ikaria, which was later acquired by Mallinckrodt, and assisted in the FDA approval process. In September 2022, the FDA approved Terlivaz (terlipressin) Injection to improve kidney function in adults with hepatorenal syndrome. The intended clients are healthcare providers and patients affected by HRS.Explore more
Orphan Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orphan Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Orphan Therapeutics is spiking on competitors!
Click to see if Orphan Therapeutics had a recent Job posting/layoffs
Orphan Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Orphan Therapeutics
Product Launch: Get notified when Orphan Therapeutics launches new products
Check if Orphan Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Orphan Therapeutics has new funding data
Earning: See what the market has to say on Orphan Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Orphan Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Orphan Therapeutics
Compare insights from companies similar to Orphan Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Orphan Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orphan Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orphan Therapeutics.
Orphan Therapeutics Tech Stack
A closer look at the technologies used by Orphan Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Orphan Therapeutics
Sign Up For FreeTo access detailed company insights
Orphan Therapeutics LLC is a privately held drug development company founded in 2003, focused on developing terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US. The company licensed its development rights for terlipressin to Ikaria, which was later acquired by Mallinckrodt, and assisted in the FDA approval process. In Sept... Read More
